• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

6.370 +1.210 (+23.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
March 17, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
March 09, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
February 24, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Pricing of Public Offering
February 19, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Proposed $100 Million Public Offering
February 19, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
February 19, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
February 11, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
November 17, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 13, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
November 04, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
November 03, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
October 16, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
October 14, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
October 14, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
October 03, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
September 29, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
September 17, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
September 02, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
August 28, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 14, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
July 30, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
July 24, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
July 09, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
June 24, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
June 23, 2025
Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones 
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
June 06, 2025
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development 
From Candel Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap